| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 206.16▲ | 203.03▲ | 202.18▲ | 200.12▲ | 203.66▲ |
| MA10 | 206.23▲ | 200.20▲ | 201.09▲ | 200.84▲ | 201.71▲ |
| MA20 | 204.44▲ | 200.75▲ | 201.31▲ | 202.45▲ | 193.12▲ |
| MA50 | 200.49▲ | 200.27▲ | 199.79▲ | 201.89▲ | 167.41▲ |
| MA100 | 200.39▲ | 199.97▲ | 201.42▲ | 191.73▲ | 151.73▲ |
| MA200 | 201.10▲ | 201.37▲ | 204.60▲ | 173.88▲ | 126.51▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.035▼ | 0.846▲ | 0.542▲ | -0.184▼ | -0.747▼ |
| RSI | 67.492▲ | 66.279▲ | 63.553▲ | 55.288▲ | 61.768▲ |
| STOCH | 62.443 | 74.053 | 69.722 | 36.466 | 60.859 |
| WILL %R | -27.578 | -9.455▲ | -9.455▲ | -12.184▲ | -32.899 |
| CCI | 35.467 | 173.709▲ | 133.377▲ | -20.104 | 19.487 |
| ▲ PSAR&MOM | $ASND PSAR Switch Up + Momentum | Set Alert |
| ▲ RSI&VOL | $ASND RSI Cross Up and Volume | Set Alert |
| RSI | $ASND RSI(14) Crossed Above 50 | Set Alert |
| MA | $ASND Price Crossed Above MA(50) | Set Alert |
| MA | $ASND Price Crossed Above MA(26) | Set Alert |
| MA | $ASND Price Crossed Above MA(13) | Set Alert |
| MA | $ASND Price Crossed Above MA(7) | Set Alert |
| ▼ GAP | $ASND Open Gap Down %3 | Set Alert |
| ▼ GAP | $ASND Open Gap Down %2 | Set Alert |
| CDL | $ASND Engulfing Candlestick Pattern Detected | Set Alert |
|
Wednesday, November 12, 2025 09:14 PM
Ascendis Pharma AS (ASND) reports robust financial performance with significant revenue growth and strategic advancements in global markets.
|
|
Wednesday, November 12, 2025 01:24 PM
Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® – Q3 2025 operating profit of €11.0 million – TransCon® CNP (navepegritide) under FDA Priority Review for the treatment ...
|
|
Wednesday, November 12, 2025 01:21 PM
Despite the revenue growth, operating expenses increased to €180.3 million from €143.4 million in the same period last year, primarily due to global commercial expansion and YORVIPATH launch ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/11/25 | 192.29 | 208.48 | 188.0711 | 206.45 | 1,907,665 |
| 12/11/25 | 200.37 | 205.00 | 198.26 | 199.22 | 666,856 |
| 11/11/25 | 195.31 | 203.00 | 195.00 | 201.16 | 519,088 |
| 10/11/25 | 199.34 | 201.00 | 195.825 | 196.01 | 463,634 |
| 07/11/25 | 200.00 | 202.41 | 195.795 | 197.74 | 316,415 |
| 06/11/25 | 197.96 | 200.55 | 196.95 | 199.28 | 264,119 |
| 05/11/25 | 205.69 | 209.00 | 196.86 | 197.75 | 388,626 |
| 04/11/25 | 200.98 | 208.41 | 197.60 | 208.24 | 406,172 |
| 03/11/25 | 202.06 | 203.7863 | 195.03 | 200.98 | 396,936 |
| 31/10/25 | 202.83 | 205.375 | 199.57 | 201.60 | 314,361 |
|
|
||||
|
|
||||
|
|